Phongpradist, RungsineeChittasupho, ChudaOkonogi, SiripornSiahaan, Teruna J.Anuchapreeda, SongyotAmpasavate, ChadaratBerkland, Cory J.2017-03-012017-03-012014-10-23Phongpradist, Rungsinee, Chuda Chittasupho, Siriporn Okonogi, Teruna Siahaan, Songyot Anuchapreeda, Chadarat Ampasavate, and Cory Berkland. "LFA-1 on Leukemic Cells as a Target for Therapy or Drug Delivery." Current Pharmaceutical Design 16.21 (2010): 2321-330.https://hdl.handle.net/1808/23320Leukemia therapeutics are aiming for improved efficacy by targeting molecular markers differentially expressed on cancerous cells. Lymphocyte function-associated antigen-1 (LFA-1) expression on various types of leukemia has been well studied. Here, the role and expression of LFA-1 on leukemic cells and the possibility of using this integrin as a target for drug delivery is reviewed. To support this rationale, experimental results were also included where cIBR, a cyclic peptide derived from a binding site of LFA-1, was conjugated to the surface of polymeric nanoparticles and used as a targeting ligand. These studies revealed a correlation of LFA-1 expression level on leukemic cell lines and binding and internalization of cIBR-NPs suggesting a differential binding and internalization of cIBR-NPs to leukemic cells overexpressing LFA-1. Nanoparticles conjugated with a cyclic peptide against an accessible molecular marker of disease hold promise as a selective drug delivery system for leukemia treatment.HL-60 cell lineLFA-1LeukemiaMolt-3 cell lineMolt-4 cell linePeptideNanoparticlesTargetingU937 cell lineArticle10.2174/138161210791920450 openAccess